Last reviewed · How we verify

NCT03382990

Stent Placement and the Risk of New-onset AF in Patients With AMI

Status unknown Last updated 26 December 2017
What this trial tests

trial testing DES or BMS in Atrial Fibrillation New Onset in 40,000 participants. Status unknown.

Timeline
1 January 2018
Primary endpoint
31 December 2018
31 December 2019

Quick facts

Lead sponsorMackay Memorial Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment40,000
Start date1 January 2018
Primary completion31 December 2018
Estimated completion31 December 2019

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

20 and older, any sex, with Atrial Fibrillation New Onset or Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The benefit of a drug-eluting stent (DES) in patients with acute myocardial infarction (AMI) is controversial. This study will aim to observe the effect of a DES on the risk of new-onset AF in patients with AMI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation New Onset

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03382990.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing